clinical trial · NCT07362186
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Locally Advanced or Metastatic GC and GCJ AdenocarcinomaLM-108 in combination with ToripalimabPaclitaxel injection intravenous infusion
brief summary
This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.
started
Apr 30, 2026
primary completion
Aug 17, 2028
completion
Sep 28, 2028
last updated
May 11, 2026
official title
A Phase III, Open-Label, Multicenter, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of LM-108 in Combination With Toripalimab Versus Paclitaxel Injection as Second-Line Therapy for CCR8-Positive Locally Advanced or Metastatic Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol